Navigation Links
Preventing Strokes With Aspirin

Based on findings of a recent study researchers suggest stroke survivors who stop taking their prescribed daily aspirin // are three-times more likely to have another stroke within the month.

Researchers studied more than 300 stroke or transient ischemic attack (TIA) patients who were on long-term aspirin therapy for preventing subsequent strokes or heart attacks. TIA is a transient stroke that lasts only a few minutes. Researchers also studied a similar population of patients taking aspirin who suffered a stroke more than six months prior. They found 13 patients in the stroke group stopped taking aspirin within four weeks before their stroke, while only four patients who suffered a stroke months earlier did. Patients with stroke or TIA were more than three-times more likely to have interrupted their aspirin regimen than patients with similar risk factors but no new stroke or TIA. Nearly 80 percent of the ischemic strokes related to aspirin discontinuation occurred in the first eight days after aspirin was stopped. The remaining number of patients had ischemic strokes within the month.

In conclusion researchers say though the risk of suffering a substantial stroke during a short period of aspirin discontinuation is probably not very high, the difference is meaningful, and patients and physicians should be informed about the potential risk.
'"/>




Page: 1

Related medicine news :

1. Preventing mental decline in the aged
2. Preventing white coat hypertension
3. Preventing Childhood Deaths
4. Preventing Vision Loss
5. Preventing Vision Loss
6. Preventing Colorectal Cancer
7. Preventing Prostate Cancer
8. Lycopene Can Help In Preventing Prostate Cancer
9. Heart Drug Also Effective In Preventing Specific Causes Of Death
10. Preventing cavities in children
11. Preventing Strokes Using Less Invasive Techniques
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Preventing Strokes With Aspirin

(Date:8/2/2015)... ... August 03, 2015 , ... A new Phase I research study is ... study is led by Kenneth G. Lucas, M.D. , chief of the division ... with colleagues at Kosair Children’s Hospital and in the UofL Department ...
(Date:8/1/2015)... ... 2015 , ... Back packs can be dangerous? Whaaat?! , Not the danger ... havoc on a kid's spine. With school starting again, most kids will be asking ... you are aware of how to help them prevent injuries by understanding backpack safety. ...
(Date:8/1/2015)... ... 01, 2015 , ... Tina Wilcoxson, owner of Freeport Maine’s Royal River Natural ... by the National Retail Federation, the largest retail trade association in the world, for ... business owners to be named as such. According to the NRF’s website, Retail Champions ...
(Date:8/1/2015)... Dallas, TX (PRWEB) , ... August 01, 2015 , ... ... support for the March4thforWellBeing foundation, making hers the very first small business donation to ... and look beautiful for over thirty years. Her legacy includes a complete line of ...
(Date:7/31/2015)... ... 2015 , ... When the weather turned hot and warm-season turfgrasses, such as ... called Leisure Time(TM) zoysia . It's nicknamed LTZ(TM) for short. Incidentally, both names ... new type of sod, Super-Sod is giving away red Adirondack chairs with the Leisure ...
Breaking Medicine News(10 mins):Health News:UofL Physicians Conducting Vaccine Trial for Children with Relapsed Tumors at Kosair Children’s Hospital 2Health News:Local AlignLife Doctor Donates Time to Check Back Packs 2Health News:Local Retail Advocate Wins National Recognition 2Health News:March4thforWellBeing Foundation Kickoff 2Health News:Super-Sod Introduces Leisure Time(TM) Zoysia Grass with an Adirondack Chair Promotion 2
... Institute researcher Jeff Tyner, Ph.D., has created a way to ... myeloid leukemia using an assay that yields results in just ... Society of Hematology annual meeting in Atlanta, on Monday, Dec. ... assay, called RAPID, because it rapidly delivers the information, has ...
... DIEGO, Dec. 10 ADVENTRX Pharmaceuticals,Inc. (Amex: ... on commercializing proprietary product candidates for the treatment,of ... M. Culley,ADVENTRX,s chief business officer, is scheduled to ... as part of a panel on Better Drugs ...
... Human Resources Professional Brings Diverse Expertise, MIAMI, ... biotherapeutic products to healthcare providers, is pleased,to announce ... Vice President of,Human Resources. Ms. Lopez was most ... & Johnson Company. Her 17-year career began,in Human ...
... States may be less likely to report a family history ... prevention strategies according to a new study. Dr. Heather Orom ... colleagues argue that as a result of being less likely ... as strong a predictor of cancer risk in immigrant populations. ...
... and post-stem cell transplantation results compared to thalidomide and ... ... Pharmaceuticals,Inc. (Nasdaq: MLNM ) reported the presentation of results from ... randomized,Phase III clinical trial. This study compared VELCADE, thalidomide and,dexamethasone (VcTD) ...
... improvement across all ... survival -, ATLANTA, Dec. 9 Millennium Pharmaceuticals,Inc. ... results from the,682 patient, randomized, Phase III VISTA(1) trial. ... for stem cell,transplantation (SCT). The trial compared VELCADE, melphalan ...
Cached Medicine News:Health News:OHSU Cancer Institute researcher develops test for targeted therapy in acute myeloid leukemia 2Health News:ADVENTRX Pharmaceuticals to Present at the 2007 RBC Capital Markets Healthcare Conference 2Health News:Novis Pharmaceuticals Hires Lisa Lopez 2Health News:Immigrant patients less likely to report family history of cancer 2Health News:Phase III Trial of VELCADE(R) (Bortezomib) for Injection Showed Dramatic Fourfold Increase in Complete Remission Rates When Combined With the Most Commonly Used U.S. Regimen in Front-Line Multiple Myeloma 2Health News:Phase III Trial of VELCADE(R) (Bortezomib) for Injection Showed Dramatic Fourfold Increase in Complete Remission Rates When Combined With the Most Commonly Used U.S. Regimen in Front-Line Multiple Myeloma 3Health News:Phase III Trial of VELCADE(R) (Bortezomib) for Injection Showed Dramatic Fourfold Increase in Complete Remission Rates When Combined With the Most Commonly Used U.S. Regimen in Front-Line Multiple Myeloma 4Health News:Phase III Trial of VELCADE(R) (Bortezomib) for Injection Showed Dramatic Fourfold Increase in Complete Remission Rates When Combined With the Most Commonly Used U.S. Regimen in Front-Line Multiple Myeloma 5Health News:Phase III Trial of VELCADE(R) (Bortezomib) for Injection Showed Dramatic Fourfold Increase in Complete Remission Rates When Combined With the Most Commonly Used U.S. Regimen in Front-Line Multiple Myeloma 6Health News:Highest Reported Complete Remission Rate of 35 Percent Achieved in a Phase III Front-Line Multiple Myeloma Trial With Velcade(R) (Bortezomib) for Injection Based Therapy 2Health News:Highest Reported Complete Remission Rate of 35 Percent Achieved in a Phase III Front-Line Multiple Myeloma Trial With Velcade(R) (Bortezomib) for Injection Based Therapy 3Health News:Highest Reported Complete Remission Rate of 35 Percent Achieved in a Phase III Front-Line Multiple Myeloma Trial With Velcade(R) (Bortezomib) for Injection Based Therapy 4Health News:Highest Reported Complete Remission Rate of 35 Percent Achieved in a Phase III Front-Line Multiple Myeloma Trial With Velcade(R) (Bortezomib) for Injection Based Therapy 5Health News:Highest Reported Complete Remission Rate of 35 Percent Achieved in a Phase III Front-Line Multiple Myeloma Trial With Velcade(R) (Bortezomib) for Injection Based Therapy 6Health News:Highest Reported Complete Remission Rate of 35 Percent Achieved in a Phase III Front-Line Multiple Myeloma Trial With Velcade(R) (Bortezomib) for Injection Based Therapy 7
(Date:8/2/2015)... Aug. 3, 2015  Lexicon Pharmaceuticals, Inc. (Nasdaq: ... TELESTAR Phase 3 clinical trial met its primary ... in treating cancer patients with carcinoid syndrome that ... of care. Telotristat etiprate was discovered using Lexicon,s ... is the company,s first discovery to complete a ...
(Date:7/31/2015)... 31, 2015 Today, the National Association ... ) issued a report urging greater accountability by ... taken against websites illegally selling medications online. As ... Identification Program Progress Report for State and Federal ... of websites illegally distribute medications and avoid retribution. ...
(Date:7/31/2015)... TAMPA, Fla. , July 31, 2015 /PRNewswire/ ... announced today that it has made a structured ... -based company specializing in milling, micronization and ... investment will help grow Powdersize,s business while simultaneously ... solutions to Xcelience,s portfolio of capabilities. ...
Breaking Medicine Technology:Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 2Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 3Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 4Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 5Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 6NABP Stresses Need for Accountability in Enforcing Internet Policies to Protect the Public From Illegal Online Drug Sellers 2NABP Stresses Need for Accountability in Enforcing Internet Policies to Protect the Public From Illegal Online Drug Sellers 3Xcelience Makes Structured Cash Investment in Powdersize 2Xcelience Makes Structured Cash Investment in Powdersize 3
... Perrigo Company (Nasdaq: PRGO ; TASE) and its ... tentative approval from the U.S. Food and Drug Administration for ... a generic version of UCB,s Xyzal® Oral Solution. Synthon believes ... generic that can entitle it to 180 days of generic ...
... -- Concord Medical Services Holdings Limited ("Concord Medical" ... of the largest network of radiotherapy and diagnostic imaging centers ... the first quarter ended March 31, 2011 (1). ... Total net revenues in the first quarter of 2011 ...
Cached Medicine Technology:Perrigo's Partner Synthon Receives FDA Tentative Approval for Levocetirizine Solution - Generic Equivalent to Xyzal® Oral Solution 2Perrigo's Partner Synthon Receives FDA Tentative Approval for Levocetirizine Solution - Generic Equivalent to Xyzal® Oral Solution 3Concord Medical Announces First Quarter 2011 Financial Results 2Concord Medical Announces First Quarter 2011 Financial Results 3Concord Medical Announces First Quarter 2011 Financial Results 4Concord Medical Announces First Quarter 2011 Financial Results 5Concord Medical Announces First Quarter 2011 Financial Results 6Concord Medical Announces First Quarter 2011 Financial Results 7Concord Medical Announces First Quarter 2011 Financial Results 8Concord Medical Announces First Quarter 2011 Financial Results 9Concord Medical Announces First Quarter 2011 Financial Results 10Concord Medical Announces First Quarter 2011 Financial Results 11Concord Medical Announces First Quarter 2011 Financial Results 12Concord Medical Announces First Quarter 2011 Financial Results 13
... Pars Plana glaucoma implant is the first ... or following a pars plana vitrectomy. The ... through a 20 gauge pars plana sclerostemy ... design accomplishment, combining the largest surface area ...
... automatic or manual kinetic and static ... or red/white stimuli/background colors. Static perimetry ... threshold strategy. Examination with pre-programmed or ... 24-2, and 10-2). Gray-scale/ Scotoma curve, ...
... lightweight enough to shuttle easily between offices ... with a goldmann standard 30 cm radius ... 79 locations (including 30-2, 24-2, and 10-2) ... suprathresholds out to 30. Easyfield is ...
The Oculus easyfield is an exciting new compact perimeter to do automatic static perimetry up to 30 degrees eccentricity. It has been designed for the combined use as a visual field screener and peri...
Medicine Products: